Study of SPX-303 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and willing to follow the study schedule.
- You have a solid tumor cancer that is advanced or has spread, and standard treatments have stopped working.
- You are able to manage most daily activities on your own (ECOG score 0 or 1).
- Your cancer has at least one tumor that can be measured on scans.
- Your kidney, liver, heart, and blood counts are within study limits.
- You do not have untreated or active brain metastases (unless they are stable and you are on low-dose steroids).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
This trial tests a new drug called LXP1788 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how it affects the body.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.